First real-world experience of adjuvant lorlatinib in resected high-risk stage I ALK-positive non-small-cell lung cancer: feasibility and tolerability (ESMO Asia 2026) - Oct 1, 2026 - Abstract #923P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK
|
|
Yudong Zhang; Fuli Li; Jieshuo Wang; Qicong Chen; Tuo Xing; Yu Jiang; Jianxing He
|